Sale of Mitsubishi Tanabe Pharma's Kashima site
First written in FY2021-Q3. 1 of 2 entries say "Achieved", first in FY2022-Q3. Latest entry: FY2022-Q3.
No other company in this theme has enough history to compare yet.
- FY2022-Q3AchievedAnnual report
「The sale was completed in December 2021.」
For Mitsubishi Tanabe Pharma's Kashima site, the sale was completed in December 2021 after its classification as held for sale. - FY2021-Q3First statedAnnual report
「At the end of the third quarter of the current consolidated fiscal year, assets held for sale and directly related liabilities primarily related to the Kashima site of Mitsubishi Tanabe Pharma Corporation, a consolidated subsidiary of the Company in the Healthcare segment. In March 2019, the Company entered into a real estate sale and purchase agreement with the buyer. As the sale was expected to take place within one year from the end of the third-quarter consolidated accounting period of the current consolidated fiscal year, the assets and liabilities were classified as held for sale.」
For Mitsubishi Tanabe Pharma's Kashima site, a real estate sale and purchase agreement was signed in March 2019, and the site was classified as held for sale because its sale was expected within one year. Completion of the sale is not stated in this filing.